AstraZeneca plc (NYSE:AZN)’s share price gapped up prior to trading on Monday . The stock had previously closed at $36.98, but opened at $37.85. AstraZeneca shares last traded at $38.99, with a volume of 4128994 shares trading hands.
Several brokerages have recently issued reports on AZN. ValuEngine raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Wolfe Research started coverage on shares of AstraZeneca in a report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Jefferies Financial Group lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Zacks Investment Research raised shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Tuesday, October 9th. Finally, Guggenheim started coverage on shares of AstraZeneca in a research note on Monday, October 8th. They issued a “buy” rating for the company. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. AstraZeneca currently has a consensus rating of “Buy” and an average price target of $40.34.
The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.54 and a current ratio of 0.72. The company has a market capitalization of $95.87 billion, a P/E ratio of 9.11, a PEG ratio of 2.02 and a beta of 0.57.
In other AstraZeneca news, major shareholder Plc Astrazeneca acquired 600,000 shares of AstraZeneca stock in a transaction dated Monday, October 22nd. The stock was bought at an average cost of $5.00 per share, for a total transaction of $3,000,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Hedge funds have recently modified their holdings of the company. HPM Partners LLC raised its holdings in shares of AstraZeneca by 50.2% in the 2nd quarter. HPM Partners LLC now owns 34,813 shares of the company’s stock valued at $1,222,000 after purchasing an additional 11,629 shares during the period. Marshall Wace LLP bought a new position in AstraZeneca in the 2nd quarter valued at about $10,519,000. Vident Investment Advisory LLC raised its holdings in AstraZeneca by 30.5% in the 2nd quarter. Vident Investment Advisory LLC now owns 69,090 shares of the company’s stock valued at $2,426,000 after acquiring an additional 16,137 shares during the period. Baird Financial Group Inc. raised its holdings in AstraZeneca by 12.0% in the 2nd quarter. Baird Financial Group Inc. now owns 56,959 shares of the company’s stock valued at $2,000,000 after acquiring an additional 6,092 shares during the period. Finally, Argent Trust Co bought a new position in AstraZeneca in the 2nd quarter valued at about $536,000. 16.10% of the stock is currently owned by institutional investors.
WARNING: “AstraZeneca (AZN) Shares Gap Up to $37.85” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/05/astrazeneca-azn-shares-gap-up-to-37-85.html.
AstraZeneca Company Profile (NYSE:AZN)
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: What is a Stop Order?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.